Kamada Ltd.

KMDA ·Healthcare, Drug Manufacturers - General, Israel
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $20.2M $14.5M $8.3M $-2.3M $-2.2M $17.1M $22.3M $22.3M
Depreciation & Amortization — — — — — — — —
Depreciation — — — — — — — —
Amortization — — — $5.4M — — — —
Stock-Based Compensation $845.0K $867.0K $1.3M $1.1M $529.0K $977.0K $1.2M $948.0K
Net Cash from Operating Activities $25.5M $47.6M $4.3M $28.6M $-8.8M $19.1M $27.6M $10.5M
Investing Activities
Capital Expenditures $9.8M $10.7M $5.9M $3.8M $3.7M $5.5M $2.3M $2.9M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-9.8M $-10.7M $-5.8M $-3.8M $-61.1M $-13.1M $-564.0K $-5.2M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $-18.3M $-13.9M $22.7M $-9.3M $18.6M $23.4M $-1.5M $-587.0K
Net Change in Cash $-3.0M $22.8M $21.4M $15.7M $-51.6M $27.5M $24.6M $5.4M
Free Cash Flow $15.6M $36.9M $-1.5M $24.8M $-12.5M $13.6M $25.3M $7.7M
← Newer Page 1 of 2 Older →